Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
hA20-humanized anti-CD20 antibody · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose level 1 | EXPERIMENTAL | 120 mg/m2 |
| Dose level 2 | EXPERIMENTAL | 200 mg/m2 |
| Dose Level 3 | EXPERIMENTAL | 375 mg/m2 |
| Dose level 1B | EXPERIMENTAL | 80 mg/m2 |
| Name | Type | Description |
|---|---|---|
| hA20-humanized anti-CD20 antibody | DRUG | once weekly iv dosing for 4 weeks |
Inclusion Criteria: * CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease
hA20-humanized anti-CD20 antibody is an investigational therapy being studied for the treatment of Non-Hodgkin's Lymphoma, specifically in patients with CD20+ disease. It is a humanized antibody designed to target CD20, a protein found on the surface of B-cells. The drug is currently in clinical development and has not been approved by regulatory authorities.
hA20-humanized anti-CD20 antibody targets the CD20 antigen, a cell surface marker expressed on B-cells. By binding to CD20, the antibody is intended to direct an immune response against CD20-positive cells, which are implicated in Non-Hodgkin's Lymphoma. This mechanism is being evaluated in clinical trials for its therapeutic potential.
hA20-humanized anti-CD20 antibody is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is responsible for the clinical development and regulatory strategy for this investigational oncology asset.
hA20-humanized anti-CD20 antibody is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains under evaluation for safety and preliminary efficacy in Non-Hodgkin's Lymphoma.
hA20-humanized anti-CD20 antibody has been studied in one completed Phase 1 clinical trial, identified by the National Clinical Trial number NCT00285428. The trial, titled 'Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma,' enrolled 82 participants in the United States. The study was controlled but not randomized or double-blinded.